• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by electroCore Inc. (Amendment)

    2/14/24 3:15:55 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ECOR alert in real time by email
    SC 13G/A 1 Electrocore13g123123t.txt ECOR 13G/A THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* ElectroCore, Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 28531P103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person?s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 28531P103 (1) Names of Reporting Persons. I.R.S. Identification Nos. of Above Persons (entities only): AWM Investment Company, Inc. (2) Check the Appropriate Box if a Member of a Group (See Instructions) (a)___ b)___ (3) SEC Use Only (4) Citizenship or Place of Organization: Delaware, United States Number of Shares Beneficially Owned by Each Reporting Person With (5) Sole Voting Power: 550,364** Common Shares 599,642**(9.99 outstanding Shares) (6) Shared Voting Power: 0** (7) Sole Dispositive Power: 550,364** Common Shares 599,642** (9.99 of outstanding Shares) (8) Shared Dispositive Power: 0** (9) Aggregate Amount Beneficially Owned by Each Reporting Person: 550,364** Common Shares, 599,642** (9.99 of Outstanding Shares) (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions): (11) Percent of Class Represented by Amount in Row (9): 9.99%** (12) Type of Reporting Person (See Instructions): IA **AWM Investment Company, Inc., a Delaware Corporation (AWM), is the investment adviser to Special Situations Cayman Fund, L.P. (CAYMAN) and Special Situations Fund III QP, L.P. (SSFQP). (CAYMAN, and SSFQP will hereafter be referred to as the Funds). As the investment adviser to the Funds, AWM holds sole voting and investment power over 128,194 shares of Common Stock of the Issuer (the Shares), 92,400 Warrants*** and 116,490 Pre-funded Warrants*** to purchase Shares held by CAYMAN, 422,170 Shares, 304,200 Warrants*** and 383,510 Pre-funded Warrants*** to purchase Shares held by SSFQP. See Items 2 and 4 of this Schedule for additional information. *** Warrants described herein may only be converted or exercised into Common Shares to the extent that the total number of Common Shares then beneficially owned does not exceed 9.99% of the outstanding shares. Item 1(a). Name Of Issuer: ElectroCore, Inc. Item 1(b). Address of Issuer?s Principal Executive Offices: 200 Forge Way ? Suite 205 Rockaway, NJ 07866 Item 2(a). Name of Person Filing: The person filing this report is AWM Investment Company, Inc., a Delaware corporation (AWM), which is the investment adviser to Special Situations Cayman Fund, L.P., a Cayman Islands Limited Partnership (CAYMAN) and Special Situations Fund III QP, L.P., a Delaware limited partnership (SSFQP). (CAYMAN and SSFQP, will hereafter be referred to as the Funds). The principal business of each Fund is to invest in equity and equity-related securities and other securities of any kind or nature. David M. Greenhouse (Greenhouse) and Adam C. Stettner (Stettner) are members of: SSCayman, L.L.C., a Delaware limited liability company (SSCAY), the general partner of CAYMAN and MGP Advisers Limited Partnership, a Delaware limited partnership (MGP), the general partner of SSFQP. Greenhouse and Stettner are also controlling principals of AWM. Item 2(b). Address of Principal Business Office or, if None, Residence: The principal business address for AWM is c/o Special Situations Funds, 527 Madison Avenue, Suite 2600, New York, NY 10022. Item 2(c). Citizenship: AWM is a Delaware Corporation. Item 2(d). Title of Class of Securities: Common Stock, Par Value $0.001 Item 2(e). CUSIP No.: 28531P103 Item 3. If This Statement Is Filed Pursuant to ??240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a: Not Applicable. Item 4. Ownership (a) Amount Beneficially Owned: 550,364** Common Shares 599,642**(9.99 of outstanding shares) (b) Percent of Class: 9.99%** (c) Number of Shares as to which the person has: (i) sole power to vote or to direct the vote: 550,364** 599,642**(9.99 of outstanding shares) (ii) shared power to vote or to direct the vote: 0** (iii) sole power to dispose or to direct the disposition of: 550,364**Common Shares 599,642**(9.99 of outstanding shares) (iv) shared power to dispose or to direct the disposition of: 0** ______________________________________________________________________ ** AWM is the investment adviser to each of the Funds. As the investment adviser to the Funds, AWM holds sole voting and investment power over 128,194 shares of Common Stock of the Issuer (the Shares), 92,400 Warrants*** and 116,490 Pre-funded Warrants*** to purchase Shares held by CAYMAN, 422,170 Shares, 304,200 Warrants*** and 383,510 Pre-funded Warrants*** to purchase Shares held by SSFQP. Greenhouse and Stettner are members of: SSCAY, the general partner of CAYMAN and MGP, the general partner of SSFQP; Greenhouse and Stettner are also controlling principals of AWM. Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ___ Item 6. Ownership of More Than Five Percent on Behalf of Another Person Not Applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person Not Applicable. Item 8. Identification and Classification of Members of the Group Not Applicable. Item 9. Notice of Dissolution of Group Not Applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 13, 2024 AWM INVESTMENT COMPANY, INC. By: /s/ Adam Stettner___ Name: Adam Stettner Title: Executive Vice President Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001) -1-
    Get the next $ECOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ECOR

    DatePrice TargetRatingAnalyst
    1/19/2022$3.00 → $2.75Buy
    HC Wainwright & Co.
    7/27/2021$3.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $ECOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gandolfo John P bought $9,018 worth of shares (1,800 units at $5.01), increasing direct ownership by 3% to 69,087 units (SEC Form 4)

      4 - electroCore, Inc. (0001560258) (Issuer)

      5/27/25 9:27:51 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Errico Thomas J. bought $47,735 worth of shares (10,000 units at $4.77), increasing direct ownership by 4% to 266,401 units (SEC Form 4)

      4 - electroCore, Inc. (0001560258) (Issuer)

      5/13/25 2:00:21 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Goldberger Daniel S bought $8,590 worth of shares (1,000 units at $8.59), increasing direct ownership by 0.35% to 290,565 units (SEC Form 4)

      4 - electroCore, Inc. (0001560258) (Issuer)

      3/18/25 10:52:56 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gandolfo John P bought $9,018 worth of shares (1,800 units at $5.01), increasing direct ownership by 3% to 69,087 units (SEC Form 4)

      4 - electroCore, Inc. (0001560258) (Issuer)

      5/27/25 9:27:51 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Errico Thomas J. bought $47,735 worth of shares (10,000 units at $4.77), increasing direct ownership by 4% to 266,401 units (SEC Form 4)

      4 - electroCore, Inc. (0001560258) (Issuer)

      5/13/25 2:00:21 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Goldberger Daniel S bought $8,590 worth of shares (1,000 units at $8.59), increasing direct ownership by 0.35% to 290,565 units (SEC Form 4)

      4 - electroCore, Inc. (0001560258) (Issuer)

      3/18/25 10:52:56 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on electroCore with a new price target

      HC Wainwright & Co. reiterated coverage of electroCore with a rating of Buy and set a new price target of $2.75 from $3.00 previously

      1/19/22 6:31:24 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ladenburg Thalmann initiated coverage on electroCore with a new price target

      Ladenburg Thalmann initiated coverage of electroCore with a rating of Buy and set a new price target of $3.00

      7/27/21 7:13:01 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Maxim Group resumed coverage on electroCore with a new price target

      Maxim Group resumed coverage of electroCore with a rating of Buy and set a new price target of $3.00

      3/13/21 8:17:18 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • electroCore Announces First Quarter 2025 Financial Results

      First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. ("NeuroMetrix"); first quarter 2025 unaudited Quell net sales of approximately $170,000  Company to host a conference call and webcast today, May 7, 2025 at 4:30 PM EDT ROCKAWAY, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic technology company, today announced financial results for the first quarter ended March 31, 2025. Recent Highlights Reported first quarter 2025 revenue of $6.7 million, a 23% increase over first quarter 2024Revenue excluding TAC-STIM totaled $

      5/7/25 4:05:00 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies

      ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the merger (the "Merger") with NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), positioning itself as a diversified leader in non-invasive health and wellness solutions. The acquisition of NeuroMetrix's Quell® Fibromyalgia Solution expands electroCore's portfolio of non-invasive bioelectronic therapies, strengthens its commercial reach — particularly within the VA Hospital System — and is expected to meaningfully increase its addressable market for the treatment of chroni

      5/2/25 8:00:00 AM ET
      $ECOR
      $NURO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • electroCore's Truvaga™ Now Works with the Apple Health app

      ROCKAWAY, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its flagship wellness product, Truvaga Plus, now works with the Apple® Health app. Truvaga Plus is a hand-held vagus nerve stimulator designed to elevate the day-to-day experience through quick and gentle activation of your vagus nerve. The product is designed to provide stress relief, improve sleep, enhance peace of mind and improve focus. Danielle Jones, Sr. Director of Direct-to-Consumer Marketing at electroCore, commented, "Using Truvaga Plus with the Apple Health app on the iPhone empowers you to better manage your hea

      5/1/25 8:00:00 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    SEC Filings

    See more
    • SEC Form SCHEDULE 13D filed by electroCore Inc.

      SCHEDULE 13D - electroCore, Inc. (0001560258) (Subject)

      5/14/25 9:02:34 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by electroCore Inc.

      10-Q - electroCore, Inc. (0001560258) (Filer)

      5/7/25 4:30:50 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • electroCore Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - electroCore, Inc. (0001560258) (Filer)

      5/7/25 4:25:21 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Stock Movement: Insider Purchase at electroCore Inc. on Jun 6

      **Analysis of Recent Insider Purchase at electroCore Inc.** An insider purchase was recently made at electroCore Inc. by Goldberger Daniel S on June 6, 2024. This transaction involved the purchase of $247,587 worth of shares, equating to 38,505 units at an average price of $6.43 per share. As a result of this purchase, Goldberger's direct ownership in the company increased by 18% to 249,565 units, as reported in the SEC Form 4 filing. Looking at the historical insider transactions at electroCore Inc., several interesting patterns emerge when analyzing the timing, price, volume, purchaser's role, and more. On August 8, 2023, Goldstein Julie Ann and Cuneo F Peter both filed SEC Form 4 report

      6/10/24 12:57:57 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Leadership Updates

    Live Leadership Updates

    See more
    • electroCore to Join Russell Microcap® Index

      ROCKAWAY, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its stock is on the preliminary additions list for inclusion in the Russell Microcap® Index after its 2024 annual reconstitution. The newly reconstituted indexes will take effect after the market close on June 28, 2024, with the newly effective reconstituted family of indices beginning trading after the open of trading on July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on May 24, 2024. "We are pleased to have been selected to join the Russell Microcap® Index," said Brian Posner, Chief Finan

      6/11/24 8:00:00 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Firefly Neuroscience, an AI-Driven Brain Health Company, Names Brian S. Posner to its Board of Directors, Upon Closing of Its Merger Transaction with WaveDancer

      FAIRFAX, Va. and TORONTO, May 29, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly"), a pioneering artificial intelligence ("AI") company developing innovative neuroscientific solutions to improve outcomes for patients with mental illnesses and neurological disorders, today announced the appointment of Brian M. Posner to its Board of Directors upon closing of its planned merger with WaveDancer, Inc. ("WaveDancer") (NASDAQ:WAVD). Firefly has entered into a definitive agreement and plan of merger (as amended, the "Merger Agreement") with WaveDancer, which has been approved by the stockholders of both companies and both companies are working towards meeting the final closing cond

      5/29/24 9:00:00 AM ET
      $ECOR
      $WAVD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Computer Software: Prepackaged Software
      Technology
    • electroCore Announces Changes to its Board of Directors

      ROCKAWAY, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Julie Bruzzone Goldstein and Tricia Wilber to the company's Board of Directors effective March 15, 2022. The Company also announced that effective March 4, 2022, Dr. Stephen Ondra is resigning from the Board to focus on his new role as Chief Medical Advisor at MITRE, and Michael Atieh will not be standing for re-election to the Board at the 2022 Annual General Meeting.   "Ms. Goldstein and Ms. Wilber are successful business leaders with proven track records, and I am pleased to welcome them to our Board," said Peter Cuneo

      3/9/22 11:30:00 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Financials

    Live finance-specific insights

    See more
    • electroCore Announces First Quarter 2025 Financial Results

      First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. ("NeuroMetrix"); first quarter 2025 unaudited Quell net sales of approximately $170,000  Company to host a conference call and webcast today, May 7, 2025 at 4:30 PM EDT ROCKAWAY, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic technology company, today announced financial results for the first quarter ended March 31, 2025. Recent Highlights Reported first quarter 2025 revenue of $6.7 million, a 23% increase over first quarter 2024Revenue excluding TAC-STIM totaled $

      5/7/25 4:05:00 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • electroCore Announces Full Year 2024 Financial Results

      Record full year 2024 net sales of $25.2 million increased 57% over $16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCoreTM in the United States Department of Veteran Affairs and United States Department of Defense (VA) and 174% increase in TruvagaTM sales Company to host a conference call and webcast today, March 12, 2025 at 5:30pm EDT ROCKAWAY, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic medicine Company and wellness company, today announced fourth quarter and full year 2024 financial results. Recent Highlights Reported record full year of 2024 revenue of $25.2 m

      3/12/25 4:05:00 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025

      ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, March 12, 2025. Management will host a webcast and conference call at 5:30 PM EDT to discuss the financial results and answer questions. Conference Call & Webcast Details Date: Wednesday, March 12, 2025Time: 5:30 PM EDTRegistration: Click here to register to receive login credentials and dial-in details. About electroCore, Inc.electroCore, Inc. is a commercial-stage bioelectronic medicine a

      3/6/25 8:00:00 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by electroCore Inc. (Amendment)

      SC 13D/A - electroCore, Inc. (0001560258) (Subject)

      6/7/24 4:33:08 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by electroCore Inc. (Amendment)

      SC 13G/A - electroCore, Inc. (0001560258) (Subject)

      2/14/24 3:15:55 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D filed by electroCore Inc.

      SC 13D - electroCore, Inc. (0001560258) (Subject)

      12/18/23 4:10:26 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care